Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P22888: Variant p.Leu502Pro

Lutropin-choriogonadotropic hormone receptor
Gene: LHCGR
Feedback?
Variant information Variant position: help 502 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Proline (P) at position 502 (L502P, p.Leu502Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In LHR; Leydig cell hypoplasia type 1; shows reduced cAMP production and ligand binding; receptor trafficking is not affected by the mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 502 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 699 The length of the canonical sequence.
Location on the sequence: help HAILIMLGGWLFSSLIAMLP L VGVSNYMKVSICFPMDVETT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         HAILIMLGGWLFSSLIAMLPLVGVSNYMKVSICFPMDVETT

Mouse                         HAIPIMLGGWIFSTLMATLPLVGVSSYMKVSICLPMDVEST

Rat                           HAIPIMLGGWLFSTLIATMPLVGISNYMKVSICLPMDVEST

Pig                           HAIPIMLGGWLFSTLIAMLPLVGVSSYMKVSICLPMDVETT

Bovine                        HAIPVMLGGWLFSTLIAVLPLVGVSNYMKVSICLPMDVEST

Chicken                       HAVPIMLGGWVFSILIAVLPLLGVSSYMKVSICLPMDIETG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 27 – 699 Lutropin-choriogonadotropic hormone receptor
Transmembrane 483 – 505 Helical; Name=4
Disulfide bond 439 – 514
Helix 500 – 503



Literature citations
A novel missense homozygous inactivating mutation in the fourth transmembrane helix of the luteinizing hormone receptor in Leydig cell hypoplasia.
Leung M.Y.-K.; Al-Muslim O.; Wu S.-M.; Aziz A.; Inam S.; Awadh M.; Rennert O.M.; Chan W.-Y.;
Am. J. Med. Genet. A 130:146-153(2004)
Cited for: VARIANT LHR PRO-502; CHARACTERIZATION OF VARIANT LCH PRO-502;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.